On Monday, ARS Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 70 to 87.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating measures price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 as they launch their biggest runs.
While the stock is not near a proper buy zone right now, see if it goes on to form and break out of a proper base.
ARS Pharmaceuticals reported 0% EPS growth in the latest quarterly report. Sales rose 4,900%.
The company holds the No. 91 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
